Drug intelligence / Profile preview

PMS-005

Development stage: Preclinical
Lead developer: Qingdao Primedicine Pharmaceutical
Modality: Small Molecules

Overview

PMS-005 is an early-stage experimental therapeutic candidate being developed by Qingdao Primedicine Pharmaceutical for the treatment of convulsions. As of 2024, the program is in the preclinical experimental phase, preceding formal pharmaceutical research and IND-enabling studies. While the developer focuses on targets such as AMPA and NMDA receptors, SREBP-1, and JNK for its broader pipeline, the specific molecular mechanism of action for PMS-005 has not been publicly disclosed.

Beyond the preview

Go deeper on PMS-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMS-005.

Explore the full profile